Dong-A Mulls Fresh Options After Allergan Ends Evogliptin Deal

With Allergan handing back the global development and sales rights of evogliptin as a NASH therapy to Dong-A, the South Korean firm is now considering an alternative business model around the DPP-4 inhibitor.